/SYRE
SYRE Stock - Spyre Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$33.40-0.21%
$0.07 (-0.21%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+43.7%upside
Target: $48.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SYRE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$33.07 – $33.73
TARGET (TP)$48.00
STOP LOSS$30.73
RISK/REWARD1:5.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.15
52W High$35.31
52W Low$10.91
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $886,000 | $2.33M | $18.74M | N/A |
| Gross Profit | N/A | $886,000 | $2.33M | $18.74M | $-1,624,000 |
| Gross Margin | N/A | 100.0% | 100.0% | 100.0% | N/A |
| Operating Income | $-208,566,000 | $-242,303,000 | $-84,781,000 | $-65,649,000 | $-81,481,000 |
| Net Income | $-208,018,000 | $-338,790,000 | $-83,815,000 | $-65,801,000 | $-80,893,000 |
| Net Margin | N/A | -38238.1% | -3598.8% | -351.1% | N/A |
| EPS | $-3.18 | $-46.15 | $-24.86 | $-25.02 | $-37.89 |
Company Overview
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
11 Bullish0 Neutral/Bearish
Price Targets
$43
Average Target
↑ 27.7% Upside
Now
$27
Low
$43
Average
$64
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | Mizuho | Initiation | Outperform | $53 |
| December 17th 2025 | Citigroup | Initiation | Buy | $64 |
| September 26th 2025 | Deutsche Bank | Initiation | Buy | $43 |
| April 8th 2025 | Leerink Partners | Initiation | Outperform | $45 |
| March 18th 2025 | Wolfe Research | Initiation | Outperform | $27 |
| September 4th 2024 | Wedbush | Initiation | Outperform | $45 |
| July 16th 2024 | Evercore ISI | Initiation | Outperform | - |
| May 2nd 2024 | Robert W. Baird | Initiation | Outperform | $50 |
| March 1st 2024 | Wells Fargo | Upgrade | Overweight | $35← $12 |
| December 20th 2023 | BTIG Research | Initiation | Buy | $32 |
| December 11th 2023 | Guggenheim | Initiation | Buy | $44 |
| December 11th 2023 | Jefferies | Initiation | Buy | $31 |
Earnings History & Surprises
SYREBeat Rate
53%
Last 15 quarters
Avg Surprise
-87.9%
EPS vs Estimate
Beats / Misses
8/7
Last 12 quarters
Latest EPS
$-0.15
Q4 2025
EPS Surprise History
Q1 24
-375.0%
$-2.28vs$-0.48
Q2 24
-33.3%
$-1.20vs$-0.90
Q3 24
+4.4%
$-0.86vs$-0.90
Q4 24
-70.0%
$-1.36vs$-0.80
Q1 25
+9.0%
$-0.81vs$-0.89
Q2 25
+2.6%
$-0.74vs$-0.76
Q3 25
+32.9%
$-0.49vs$-0.73
Q4 25
+77.9%
$-0.15vs$-0.68
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.66 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.68 | $-0.15 | +77.9% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.73 | $-0.49 | +32.9% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.76 | $-0.74 | +2.6% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.89 | $-0.81 | +9.0% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.80 | $-1.36 | -70.0% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.90 | $-0.86 | +4.4% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.90 | $-1.20 | -33.3% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $-0.48 | $-2.28 | -375.0% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.84 | $-9.34 | -1011.9% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-4.50 | $-1.66 | +63.1% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-4.50 | $-4.89 | -8.6% | ✗ MISS |
Q4 2022 | Dec 30, 2022 | $-5.71 | $-7.20 | -26.1% | ✗ MISS |
Q3 2022 | Sep 29, 2022 | $-6.25 | $-4.84 | +22.6% | ✓ BEAT |
Q2 2022 | Jun 29, 2022 | $-7.95 | $-6.79 | +14.6% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | — | $-9.26 | — | — |
Q4 2021 | Dec 30, 2021 | $-8.54 | $-10.36 | -21.3% | ✗ MISS |
Q3 2021 | Sep 29, 2021 | — | $-7.72 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-2.60 | — | — |
Latest News
Mizuho Initiates Coverage On Spyre Therapeutics with Outperform Rating, Announces Price Target of $53
📈 PositiveBenzinga•Dec 18, 2025, 09:31 AM
Citigroup Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $64
📈 PositiveBenzinga•Dec 17, 2025, 03:11 PM•Also:
Jones Trading Upgrades Spyre Therapeutics to Buy, Announces $64 Price Target
📈 PositiveBenzinga•Dec 1, 2025, 01:17 PM
Spyre Therapeutics Q3 EPS $(0.15) Beats $(0.74) Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:49 PM
Spyre Therapeutics Announces Interim Phase 1 Data From First-In-Human Trial Of SPY003Across 59 Participants; SPY003 Well Tolerated Throughout All Doses
📈 PositiveBenzinga•Nov 4, 2025, 09:15 PM
Spyre Therapeutics Releases New Data From Its Phase 1 Study Of SPY072, An anti-TL1a Antibody For Rheumatic Diseases Showing SPY072 Was Well Tolerated, Maintained Strong Tl1a Suppression, And Supports Quarterly Or Twice-Yearly Dosing
📈 PositiveBenzinga•Oct 24, 2025, 12:04 PM
Reported Earlier, Spyre Therapeutics Prices $275M Public Offering Of 14,864,865 Common Shares At $18.50 Each To Advance IBD Pipeline
📈 PositiveBenzinga•Oct 14, 2025, 04:59 AM
Spyre Therapeutics Reveals Proposed Public Offering of its Common Stock And Pre-Funded Warrants; No Size Disclosed
➖ NeutralBenzinga•Oct 13, 2025, 08:03 PM
Reported Sunday, Spyre Therapeutics Unveils Phase 1 SPY002 Data Supporting Long-Acting Dosing For IBD And Promising Preclinical Combination Results
📈 PositiveBenzinga•Oct 6, 2025, 06:33 AM
Deutsche Bank Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $43
📈 PositiveBenzinga•Sep 26, 2025, 11:38 AM•Also:
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $70 Price Target
📈 PositiveBenzinga•Sep 16, 2025, 10:43 AM
Spyre Therapeutics Doses First Patient In Phase 2 SKYWAY Trial Of SPY072, An Anti-TL1A Antibody For Rheumatic Diseases
📈 PositiveBenzinga•Sep 15, 2025, 12:02 PM
Frequently Asked Questions about SYRE
What is SYRE's current stock price?
Spyre Therapeutics, Inc. (SYRE) is currently trading at $33.40 per share. The stock has moved -0.21% today.
What is the analyst price target for SYRE?
The average analyst price target for SYRE is $48.00, based on 1 analyst.
What sector is Spyre Therapeutics, Inc. in?
Spyre Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SYRE's market cap?
Spyre Therapeutics, Inc. has a market capitalization of $2.02 billion, making it a mid-cap company.
Does SYRE pay dividends?
No, Spyre Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
ARDX
Ardelyx, Inc.
$5.68
Mkt Cap: $1.4B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
MAZE
Maze Therapeutics, Inc.
$41.71
Mkt Cap: $2.0B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
UPB
Upstream Bio, Inc.
$29.35
Mkt Cap: $1.6B
WVE
Wave Life Sciences Ltd.
$15.98
Mkt Cap: $2.6B
ZYME
Zymeworks Inc.
$27.23
Mkt Cap: $2.0B
Explore stocks similar to SYRE for comparison